Publication

Combination of ruthenium(II)-arene complex [Ru(eta(6)-p-cymene)Cl-2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

Related publications (46)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Nonsteroidal Anti-inflammatory-Organometallic Anticancer Compounds

Paul Joseph Dyson, Rosario Scopelliti, Mylène Soudani, Emilia Paunescu, Sarah Mcarthur

Compounds that combine metal-based drugs with covalently linked targeted organic agents have been shown, in some instances, to exhibit superior anticancer properties compared to the individual counterparts. Within this framework, we prepared a series of or ...

Amer Chemical Soc2016

This paper proposes a novel imaging biomarker of lung cancer relapse from 3-D texture analysis of CT images. Three-dimensional morphological nodular tissue properties are described in terms of 3-D Riesz-wavelets. The responses of the latter are aggregated ...

IEEE2016

, , ,

Tumor vasculature is known to be poorly organized leading to increased leakage of molecules to the extravascular space. This process can potentially increase interstitial fluid pressure impairing intra-tumoral blood flow and oxygen supply, and can affect d ...

2015

Anticancer Organometallic Osmium(II)-p-cymene Complexes

Paul Joseph Dyson, Rosario Scopelliti, Patrycja Nowak-Sliwinska, Catherine Marie Amélie Clavel, Emilia Paunescu

Osmium compounds are attracting increasing attention as potential anticancer drugs. In this context, a series of bifunctional organometallic osmium(II)-p-cymene complexes functionalized with alkyl or perfluoroalkyl groups were prepared and screened for the ...

Wiley-V C H Verlag Gmbh2015

The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed tumor and endothelial cells. This phenomenon is part of t ...

Nature Publishing Group2015

Organometallic rhodium(III) and iridium(III) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands

Paul Joseph Dyson, Rosario Scopelliti, Tina Riedel, Agnese Petrini

A series of half-sandwich cyclopentadienyl rhodium(III) and iridium(III) complexes of the type [CpM(curc/bdcurc) Cl] and [CpM(curc/bdcurc)(PTA)][SO3CF3], in which Cp* = pentamethylcyclopentadienyl, curcH = curcumin and bdcurcH = bisdemethoxycurcumin as O ...

2015

, ,

A series of novel ruthenium(II) arene RAPTA type derivatives (arene = cymene, hexamethylbenzene) containing curcumin-based ligands (curcH = curcumin, bdcurcH = bisdemethoxycurcumin) and PTA (1,3,5-triaza-7-phosphaadamantane) have been synthesized and fully ...

2014

Chloroquine (CQ) has been evaluated as an autophagy blocker for cancer treatment, but it is unknown if it acts solely by inhibiting cancer cell autophagy. We report that CQ reduced tumor growth but improved the tumor milieu. By normalizing tumor vessel str ...

Elsevier2014

, ,

Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin, carboplatin and oxaliplatin, a variety of other metal-based anti-cancer compounds are being investigated. In particular, a number of ruthenium-based compounds have been id ...

2014

Rational design of organic and organometallic thermoresponsive or tumor-selective anticancer drugs and their in vitro and in vivo biological evaluation

Catherine Marie Amélie Clavel

Conventional chemotherapy leads to severe side-effects such as nephrotoxicity, nausea and vomiting and fatigue along with drug resistance. Alkylating agents used to treat cancer were even shown to provoke second cancers, often years after the end of chemot ...

EPFL2014